A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Phase 2 Recruiting 45 enrolled Fujian Akeylink Biotechnology Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131 tablets in patients with chronic hepatitis B

Timeline

Start: 2023-12-26
Primary completion: 2025-04-01
Completion: 2025-05-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GST-HG131	Small molecule	—	—

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Summary

Timeline

Drugs

Indications